Evidence map›Paper›PMID 30518317›Full record

ArticleBMC microbiology2018

USA300 Staphylococcus aureus persists on multiple body sites following an infection.

Timothy D Read, Robert A Petit, Zachary Yin, Tuyaa Montgomery, Moira C McNulty, Michael Z David

Open access · goldAbstract read
In one paragraph

Article in BMC microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 21 citations in OpenAlex.

  1. Prevalence and antimicrobial susceptibility ofOne health (Amsterdam, Netherlands) · 2026
    Article
  2. Methicillin-resistantiScience · 2026
    Review
  3. Article
  4. CharacterizingmSystems · 2025
    Article
  5. Article
  6. Review
  7. How to survive pig farming: Mechanism of SCCFrontiers in microbiology · 2022
    Article
  8. Article
  9. Epidemiology of the Staphylococcus aureus CA-MRSA USA300 in Belgium.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2021
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Bacterial signaling as an antimicrobial target.Current opinion in microbiology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Timothy D ReadDepartment of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA.
Robert A PetitDepartment of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA.
Zachary YinDepartment of Pediatrics, Section of Infectious Diseases, University of Chicago, Chicago, IL, USA.
Tuyaa MontgomeryDepartment of Pediatrics, Section of Infectious Diseases, University of Chicago, Chicago, IL, USA.
Moira C McNultyDepartment of Medicine, Section of Infectious Diseases and Global Health, University of Chicago, Chicago, IL, USA.
Michael Z DavidDepartment of Medicine, Division of Infectious Diseases, University of Pennsylvania, Philadelphia, PA, USA. michael.david@uphs.upenn.edu.ORCID 0000-0002-1926-7800
University of Chicago · USEmory University · USUniversity of Pennsylvania · US

Funding

Recurrent MRSA Infections: A Study of Risk Factors and Molecular EpidemiologyK23AI095361 · NIAID · UNIVERSITY OF CHICAGO · PI DAVID, MICHAEL ZDENEK · 2011 to 2015
$633k
Genomics-based prediction of antibiotic failure in S. aureus infectionsR21AI121860 · NIAID · EMORY UNIVERSITY · PI READ, TIMOTHY D., SATOLA, SARAH W · 2016 to 2017
$429k
NIAID NIH HHS K23 AI095361NIAID NIH HHS R21 AI121860
6 · The paper itself

Abstract

backgroundUSA300 methicillin-resistant Staphylococcus aureus (MRSA) is a community- and hospital-acquired pathogen that frequently causes infections but also can survive on the human body asymptomatically as a part of the normal microbiota. We devised a comparative genomic strategy to track colonizing USA300 at different body sites after an initial infection. We sampled ST8 S. aureus from subjects at the site of a first known MRSA infection. Within 60 days of this infection and again 12 months later, each subject was tested for asymptomatic colonization in the nose, throat and perirectal region. 93 S. aureus strains underwent whole genome shotgun sequencing.

resultsAmong 28 subjects at the initial sampling time, we isolated S. aureus from the nose, throat and perirectal sites from 15, 11 and 15 of them, respectively. Twelve months later we isolated S. aureus from 9 subjects, with 6, 3 and 3 strains from the nose, throat and perirectal area, respectively. Genome sequencing revealed that 23 patients (ages 0-66 years) carried USA300 intra-subject lineages (ISLs), defined as having an index infection isolate and closely related colonizing strains. Pairwise distance between strains in different ISLs was 48 to 162 single nucleotide polymorphisms (SNPs) across the core regions of the chromosome, whereas within the same ISL it was 0 to 26 SNPs. Strains in ISLs from the same subject differed in plasmid and prophage content, and contained deletions that removed the mecA-containing SCCmec and ACME regions. Five strains contained frameshift mutations in agr toxin-regulating genes. Persistence of an ISL was not associated with clinical or demographic subject characteristics. We inferred that colonization with the ISL occurred about 18 weeks before the first assessment of asymptomatic colonization.

conclusionsClonal lineages of USA300 may continue to colonize people at one or more anatomic sites up to a year after an initial infection and experience loss of the SCCmec, loss and gain of other mobile genetic elements, and mutations in the agr operon.

Indexed as

AdolescentAdultAgedAnti-Bacterial AgentsCarrier StateChildChild, PreschoolDrug Resistance, BacterialFemaleGenome, BacterialGenotypeHumansInfantMaleMethicillin-Resistant Staphylococcus aureusMiddle AgedAnti-Bacterial AgentsAntibiotic resistanceColonizationMRSAPhagePlasmidsSSTIStaphylococcus aureusUSA300

Identifiers

PMID30518317
PMCPMC6282268
OpenAlexW2902539764

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.